Kindred Biosciences Priced, Nasdaq: KIN
Biotech developing pet therapeutics for pain and severe itching.
Industry: Health Care
First Day Return: +70.7%
Industry: Health Care
KIN
Biotech developing pet therapeutics for pain and severe itching.
| IPO Data | |
|---|---|
| IPO File Date | 11/08/2013 |
| Offer Price | $7.00 |
| Price Range $6.00 - $8.00 | |
| Offer Shares (mm) | 7.5 |
| Deal Size ($mm) | $53 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 12/11/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $53 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Burlingame, CA, United States |
| Founded | 2012 |
| Employees at IPO | 9 |
| Website www.kindredbio.com | |
IPO News for Kindred Biosciences
Kindred Biosciences (KIN) Performance
